肽类物质相关内容在社交媒体平台上大规模传播，已构成全球公共卫生风险。澳大利亚治疗商品管理局报告称，一名患者因使用未获批的肽类物质而遭遇不受控呕吐，导致潜在致命的食道撕裂1。这起严重不良事件突显了这类产品流通的危害性。
社交媒体对肽类物质的推广规模令人担忧。Instagram平台上发现超过13万篇相关帖子，而TikTok上肽类相关内容的浏览量超过2.3亿次1。然而，在线销售的许多肽类产品质量难以保证。独立实验室测试显示，标注为retatrutide的肽类产品的实际剂量从51%到190%不等存在严重偏差1，某些样本甚至完全不含标注的活性成分或含有完全不同的物质1。这些问题凸显了产品成分与标签不符的风险，以及社交媒体平台在防止虚假或危险产品销售中的监管缺陷。
Peptide-related content has proliferated across social media platforms, creating a significant global public health concern. Australia's Therapeutic Goods Administration reported a case in which an individual using an unapproved peptide substance experienced uncontrolled vomiting that led to a potentially fatal esophageal tear.1 The scale of online promotion is substantial, with researchers identifying over 130,000 peptide-related posts on Instagram and more than 230 million views of peptide-related content on TikTok.1
A critical issue compounding these risks is the inconsistency and misrepresentation of products sold online. Independent laboratory testing revealed that peptide products labeled as retatrutide contained dosages ranging from 51 percent to 190 percent of stated amounts.1 Additionally, some peptide product samples tested were found to contain no trace of their labeled active ingredients or contained entirely different substances.1 These discrepancies underscore the vulnerability of consumers purchasing unregulated products through social media channels and highlight the inadequate oversight of peptide sales and distribution online.
评论
还没有评论，欢迎留下第一条。